RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $42

Benzinga Newsdesk www.benzinga.com Negative 94.2%

Neg 94.2% Neu 0% Pos 0%

RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $50 to $42.